Poseida Therapeutics, Inc. Stock News

Poseida Therapeutics, Inc. (PSTX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated neurotoxic

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 235.29% and 5,715.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo

Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.

SAN DIEGO , Oct. 5, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create

Poseida announced a collaboration agreement on Aug.3 focused on allogeneic CAR-T Program in hematologic cancers with Roche, potentially worth $6 billion; $110 million upfront, $110 million in near-ter

Poseida Therapeutics is developing P-BCMA-ALLO1 for multiple myeloma and P-MUC1C-ALLO1 for solid tumors; data readouts from both of these candidates are expected in the 2nd half of 2022. Poseida estab

Source: Shutterstock Poseida Therapeutics (NASDAQ: PSTX ) stock is soaring on Wednesday after the clinical-stage biotechnology company announced a deal with Roche (OTCMKTS: RHHBY ). The agreement with

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

Poseida Therapeutics press release (PSTX): Q4 GAAP EPS of $0.02.Revenue of $31.2M.As of December 31, 2021, cash and cash equivalents balance was $206.3 million, which does not include…

SAN DIEGO, March 10, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced updates and…

Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of 105.88% and 31.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for th

SAN DIEGO, March 1, 2022 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that the…